GSK revives interest in Blenrep with new Phase III data

Having pulled its multiple myeloma drug Blenrep (belantamab mafodotin) off the US market in 2022, and getting a negative recommendation from the European regulator in September this year, UK pharma major GSK (LSE: GSK) has come back with promising new clinical data.

GSK today announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head Phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma.

The trial met its primary endpoint of progression-free survival (PFS) and showed that belantamab mafodotin when combined with bortezomib plus dexamethasone (BorDex) significantly extended the time to disease progression or death versus daratumumab plus BorDex, an existing standard of care for relapsed/refractory multiple myeloma. A strong and clinically meaningful overall survival (OS) trend with nominal p value < 0.0005 was also observed at the time of this analysis, and the trial continues to follow up for OS.